company background image
ATB logo

Antibiotice BVB:ATB Stock Report

Last Price

RON 2.10

Market Cap

RON 1.4b

7D

-3.0%

1Y

13.2%

Updated

15 Apr, 2025

Data

Company Financials

Antibiotice S.A.

BVB:ATB Stock Report

Market Cap: RON 1.4b

ATB Stock Overview

Produces and sells medicinal products in Romania. More details

ATB fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance4/6
Financial Health5/6
Dividends3/6

Rewards

Trading at 50.9% below our estimate of its fair value

Earnings are forecast to grow 15.33% per year

Earnings grew by 22.6% over the past year

Risk Analysis

Dividend of 3.95% is not well covered by free cash flows


Antibiotice S.A. Competitors

Zentiva

BVB:SCD

RON 3.2b

Biofarm

BVB:BIO

RON 650.3m

S.C. Sintofarm

BVB:SINT

RON 16.6m

PharmaSGP Holding

XTRA:PSG

€287.8m

Price History & Performance

Summary of share price highs, lows and changes for Antibiotice
Historical stock prices
Current Share PriceRON 2.10
52 Week HighRON 3.44
52 Week LowRON 1.82
Beta0.11
1 Month Change-9.48%
3 Month Change-19.23%
1 Year Change13.21%
3 Year Change279.06%
5 Year Change320.00%
Change since IPO2,448.91%

Recent News & Updates

Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last Year

Apr 04
Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last Year

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 23
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Recent updates

Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last Year

Apr 04
Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last Year

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 23
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Jun 07
Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

Jan 30
Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

Jan 13
We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Aug 16
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Is Antibiotice (BVB:ATB) A Risky Investment?

Jun 08
Is Antibiotice (BVB:ATB) A Risky Investment?

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Feb 11
Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Jan 12
Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 16
Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 24
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Shareholder Returns

ATBRO PharmaceuticalsRO Market
7D-3.0%0.2%0.08%
1Y13.2%-15.9%-1.9%

Return vs Industry: ATB exceeded the RO Pharmaceuticals industry which returned -17.2% over the past year.

Return vs Market: ATB exceeded the RO Market which returned -2.6% over the past year.

Price Volatility

Is ATB's price volatile compared to industry and market?
ATB volatility
ATB Average Weekly Movement3.4%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.7%
10% most volatile stocks in RO Market10.9%
10% least volatile stocks in RO Market2.7%

Stable Share Price: ATB has not had significant price volatility in the past 3 months compared to the RO market.

Volatility Over Time: ATB's weekly volatility (3%) has been stable over the past year.

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

About the Company

FoundedEmployeesCEOWebsite
19551,350Ioan Naniwww.antibiotice.ro

Antibiotice S.A. produces and sells medicinal products in Romania. The company produces medicines for a range of therapeutic areas, such as cardiovascular system, alimentary tract and metabolism, musculo-skeletal system, nervous system, antiinfectives, respiratory system, dermatological, food supplements, sensory organs, genito-urinary apparatus and sexual hormones, varia, and blood and blood forming organs, as well as veterinary medicinal products. It offers its products in the form of sterile injectable powders, capsules, tablets, ointments, gels, creams, and suppositories.

Antibiotice S.A. Fundamentals Summary

How do Antibiotice's earnings and revenue compare to its market cap?
ATB fundamental statistics
Market capRON 1.41b
Earnings (TTM)RON 99.42m
Revenue (TTM)RON 686.57m

14.2x

P/E Ratio

2.1x

P/S Ratio

Is ATB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATB income statement (TTM)
RevenueRON 686.57m
Cost of RevenueRON 234.11m
Gross ProfitRON 452.45m
Other ExpensesRON 353.03m
EarningsRON 99.42m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 16, 2025

Earnings per share (EPS)0.15
Gross Margin65.90%
Net Profit Margin14.48%
Debt/Equity Ratio15.7%

How did ATB perform over the long term?

See historical performance and comparison

Dividends

3.9%

Current Dividend Yield

60%

Payout Ratio

Does ATB pay a reliable dividends?

See ATB dividend history and benchmarks
When do you need to buy ATB by to receive an upcoming dividend?
Antibiotice dividend dates
Ex Dividend DateSep 25 2025
Dividend Pay DateOct 08 2025
Days until Ex dividend161 days
Days until Dividend pay date174 days

Does ATB pay a reliable dividends?

See ATB dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/15 07:58
End of Day Share Price 2025/04/15 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Antibiotice S.A. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raluca NegoescuAlpha Finance Romania
Vladimira UrbankovaErste Group Bank AG
Alex DodoiSSIF BRK Financial Group S.A.